Panorama actual de la producción científica sobre terapias y tratamientos contra Helicobacter pylori: Artículo de revisión cienciométrica
DOI:
https://doi.org/10.18041/2619-4465/interfaces.1.13392Palabras clave:
Helicobacter pylori, Terapias, Tratamientos, Cienciometría, Resistencia a los antibióticosResumen
La infección por Helicobacter pylori representa una preocupación significativa de salud pública debido a su alta prevalencia global y su fuerte asociación con enfermedades gastrointestinales, incluyendo gastritis crónica, úlceras pépticas y cáncer gástrico. A pesar del creciente interés científico en esta bacteria, ninguna revisión cienciométrica reciente se había centrado exclusivamente en las terapias y tratamientos dirigidos a su erradicación. Este estudio realizó un análisis cienciométrico de la producción científica entre 2004 y 2024, utilizando las bases de datos Web of Science y Scopus. Se identificaron y analizaron un total de 1,128 artículos únicos utilizando herramientas como Python, Gephi e Inkscape para visualizar tendencias, redes de colaboración y evolución del conocimiento. Los resultados muestran un crecimiento constante en las publicaciones, con China y Estados Unidos liderando la producción científica. Autores como Malfertheiner P. y Graham D.Y. se destacan como figuras clave en el campo, mientras que revistas como Helicobacter y World Journal of Gastroenterology son los principales medios de difusión. El análisis de redes identificó temas centrales como la resistencia a los antibióticos, las terapias cuádruples con bismuto y el papel de los probióticos como coadyuvantes. Este estudio proporciona una visión estructurada de los avances en el tratamiento de H. pylori, ofreciendo una base sólida para que investigadores y profesionales de la salud identifiquen áreas prioritarias y orienten futuras investigaciones hacia el desarrollo de terapias más eficaces y personalizadas.
Descargas
Referencias
[1]B. Zhong et al., “Impact of Helicobacter pylori infection on neoadjuvant chemotherapy in locally advanced gastric cancer: a retrospective analysis,” BMC Cancer, vol. 25, no. 1, p. 157, Jan. 2025, doi: 10.1186/s12885-025-13494-5.
[2]M. S. Hemeda et al., “Efficacy of Cerebroplacental Doppler Ratio in Predicting Adverse Fetal Outcomes in Cases of Fetal Growth Restriction Multicenter Study,” J Clin Ultrasound, May 2025, doi: 10.1002/jcu.24076.
[3]M. S. Hemeda et al., “Investigation of metronidazole resistance-associated mutations and virulence genotypes in helicobacter pylori isolates from the Egyptian population: A cross-sectional study,” J Infect Chemother, vol. 31, no. 2, p. 102533, Feb. 2025, doi: 10.1016/j.jiac.2024.10.001.
[4]H. Sati et al., “The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance,” Lancet Infect Dis, Apr. 2025, doi: 10.1016/S1473-3099(25)00118-5.
[5]S. Zhang et al., “Fucoidan-modified antibiotic-free nanovesicles: A multidimensional approach to eradicate intracellular and extracellular Helicobacter pylori and restore gastrointestinal homeostasis,” Int J Biol Macromol, vol. 307, no. Pt 2, p. 141786, May 2025, doi: 10.1016/j.ijbiomac.2025.141786.
[6]J. Cao et al., “Fucoidan from sea cucumber cooking liquid: Structural analysis, physicochemical properties, and anti-Helicobacter pylori potential,” Int J Biol Macromol, vol. 306, no. Pt 4, p. 141593, May 2025, doi: 10.1016/j.ijbiomac.2025.141593.
[7]Q. Sun et al., “infection: a dynamic process from diagnosis to treatment,” Front Cell Infect Microbiol, vol. 13, p. 1257817, Oct. 2023, doi: 10.3389/fcimb.2023.1257817.
[8]A. Elbehiry et al., “Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges,” Antibiotics (Basel), vol. 12, no. 2, Jan. 2023, doi: 10.3390/antibiotics12020191.
[9]S. Yang, S. Hao, H. Ye, and X. Zhang, “Cross-talk between and gastric cancer: a scientometric analysis,” Front Cell Infect Microbiol, vol. 14, p. 1353094, Jan. 2024, doi: 10.3389/fcimb.2024.1353094.
[10]V. K. Singh, P. Singh, M. Karmakar, J. Leta, and P. Mayr, “The journal coverage of Web of Science, Scopus and Dimensions: A comparative analysis,” Scientometrics, vol. 126, no. 6, pp. 5113–5142, Jun. 2021, doi: 10.1007/s11192-021-03948-5.
[11]S. O’Hern and N. Estgfaeller, “A scientometric review of powered micromobility,” Sustainability, vol. 12, no. 22, p. 9505, Nov. 2020, doi: 10.3390/su12229505.
[12]L. Xu, C. Ao, B. Liu, and Z. Cai, “Ecotourism and sustainable development: a scientometric review of global research trends,” Environ Dev Sustain, vol. 25, no. 4, pp. 2977–3003, 2023, doi: 10.1007/s10668-022-02190-0.
[13]C. Yu, J. Qiu, M. Xiong, C. Ou, M. Zeng, and H. Song, “Trends in -related gastric ulcer research from 2012 to 2022: A bibliometric and visual analysis,” Front Med (Lausanne), vol. 9, p. 1027534, Nov. 2022, doi: 10.3389/fmed.2022.1027534.
[14]C. Yuan et al., “Research on antibiotic resistance in : a bibliometric analysis of the past decade,” Front Microbiol, vol. 14, p. 1208157, Jun. 2023, doi: 10.3389/fmicb.2023.1208157.
[15]E. Myllyluoma et al., “Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study,” Aliment Pharmacol Ther, vol. 21, no. 10, pp. 1263–1272, May 2005, doi: 10.1111/j.1365-2036.2005.02448.x.
[16]P. Malfertheiner et al., “Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report,” Gut, vol. 61, no. 5, pp. 646–664, May 2012, doi: 10.1136/gutjnl-2012-302084.
[17]P. Malfertheiner et al., “Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial,” Lancet, vol. 377, no. 9769, pp. 905–913, Mar. 2011, doi: 10.1016/S0140-6736(11)60020-2.
[18]J.-C. Yang, C.-W. Lu, and C.-J. Lin, “Treatment of Helicobacter pylori infection: Current status and future concepts,” World Journal of Gastroenterology, vol. 20, no. 18, pp. 5283–5293, May 2014, doi: 10.3748/wjg.v20.i18.5283.
[19]I. Thung et al., “Review article: the global emergence of Helicobacter pylori antibiotic resistance,” Aliment Pharmacol Ther, vol. 43, no. 4, pp. 514–533, Feb. 2016, doi: 10.1111/apt.13497.
[20]W. Z. Liu et al., “Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection,” Helicobacter, vol. 23, no. 2, p. e12475, Apr. 2018, doi: 10.1111/hel.12475.
[21]L. Yan et al., “Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up,” Gastroenterology, vol. 163, no. 1, pp. 154–162.e3, Jul. 2022, doi: 10.1053/j.gastro.2022.03.039.
[22]X.-Z. Zhou et al., “Large-scale, national, family-based epidemiological study on infection in China: the time to change practice for related disease prevention,” Gut, vol. 72, no. 5, pp. 855–869, May 2023, doi: 10.1136/gutjnl-2022-328965.
[23]K. Jia et al., “and immunotherapy for gastrointestinal cancer,” Innovation (Camb), vol. 5, no. 2, p. 100561, Mar. 2024, doi: 10.1016/j.xinn.2023.100561.
[24]X. Zhang et al., “Chitosan-modified molybdenum selenide mediated efficient killing of Helicobacter pylori and treatment of gastric cancer,” Int J Biol Macromol, vol. 275, no. Pt 1, p. 133599, Aug. 2024, doi: 10.1016/j.ijbiomac.2024.133599.
[25]H. Zhou, Y. Li, and W. Lu, “Treatment Effects of Bifidobacterium Quadruple Viable Tablets Combined With Quadruple Therapy on -Infected Peptic Ulcer in Children,” Clin Pediatr (Phila), vol. 64, no. 1, pp. 64–71, Jan. 2025, doi: 10.1177/00099228241248717.
[26]A. A. Agarwal et al., “Crystal structure of dihydroorotate dehydrogenase from Helicobacter pylori with bound flavin mononucleotide,” Acta Crystallogr F Struct Biol Commun, vol. 81, no. Pt 3, pp. 108–117, Mar. 2025, doi: 10.1107/S2053230X25000858.
[27]J. Tan et al., “pH-Responsive Polymeric Micelle Dynamic Complexes for Selective Killing of,” Biomacromolecules, vol. 24, no. 12, pp. 5551–5562, Dec. 2023, doi: 10.1021/acs.biomac.2c01374.
[28]L. Olmedo et al., “Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for infection between 2013 and 2021: results from the European registry on management (Hp-EuReg),” Gut, vol. 74, no. 1, pp. 15–25, Dec. 2024, doi: 10.1136/gutjnl-2024-332804.
[29]K. Kotilea et al., “Helicobacter pylori infection found during upper endoscopy performed for the diagnosis of celiac, inflammatory bowel diseases, and eosinophilic esophagitis: A multicenter pediatric European study,” Helicobacter, vol. 29, no. 3, p. e13092, May-Jun 2024, doi: 10.1111/hel.13092.
[30]M. Kato et al., “Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition,” Helicobacter, vol. 24, no. 4, p. e12597, Aug. 2019, doi: 10.1111/hel.12597.
[31]A. M. Asaad et al., “Susceptibility patterns and virulence genotypes of affecting eradication therapy outcomes among Egyptian patients with gastroduodenal diseases,” World J Gastroenterol, vol. 29, no. 19, pp. 2950–2960, May 2023, doi: 10.3748/wjg.v29.i19.2950.
[32] H. Demirci et al., “Helicobacter Pylori Colonization Density is an Important Risk Factor for Eradication Therapy,” J Gastrointestin Liver Dis, vol. 31, no. 2, pp. 163–167, Jun. 2022, doi: 10.15403/jgld-4238.
[33]H. Nordenstedt et al., “Helicobacter pylori-negative gastritis: prevalence and risk factors,” Am J Gastroenterol, vol. 108, no. 1, pp. 65–71, Jan. 2013, doi: 10.1038/ajg.2012.372.
[34]A. G. Gravina, R. M. Zagari, C. De Musis, L. Romano, C. Loguercio, and M. Romano, “and extragastric diseases: A review,” World J Gastroenterol, vol. 24, no. 29, pp. 3204–3221, Aug. 2018, doi: 10.3748/wjg.v24.i29.3204.
[35]R. Deguchi, T. Ueda, E. Teramura, Y. Arase, and T. Kagawa, “Colorectal mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori eradication treatment: a report of 5 cases,” J Gastrointestin Liver Dis, vol. 33, no. 3, pp. 426–428, Sep. 2024, doi: 10.15403/jgld-5672.
[36]C. Chen, “Science mapping: A systematic review of the literature,” J. Data Inf. Sci., vol. 2, no. 2, pp. 1–40, Mar. 2017, doi: 10.1515/jdis-2017-0006.
[37]N. J. van Eck and L. Waltman, “Software survey: VOSviewer, a computer program for bibliometric mapping,” Scientometrics, vol. 84, no. 2, pp. 523–538, Aug. 2010, doi: 10.1007/s11192-009-0146-3.
[38]V. Mahachai et al., “Helicobacter pylori management in ASEAN: The Bangkok consensus report,” J Gastroenterol Hepatol, vol. 33, no. 1, pp. 37–56, Jan. 2018, doi: 10.1111/jgh.13911.
[39]E. Goni et al., “The influence of gastric atrophy on Helicobacter pylori antibiotics resistance in therapy-naïve patients,” Front. Microbiol., vol. 13, p. 938676, Sep. 2022, doi: 10.3389/fmicb.2022.938676.
[40]P. Malfertheiner et al., “Management of infection: the Maastricht VI/Florence consensus report,” Gut, Aug. 2022, doi: 10.1136/gutjnl-2022-327745.
[41]N. García-Morales et al., “Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Management,” J Clin Med, vol. 12, no. 13, Jun. 2023, doi: 10.3390/jcm12134363.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2025 Interfaces
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
